JCB, Volume 16, Number 1, 2010 Editorial Vol.16 No. 1 (2010) Time for a new business model? Yali Friedman In the relatively short history of the biotechnology industry, new business models have emerged every few years. Some have been little more than short-lived marketing or investment-attract Abstract Download PDF Commentary Vol.16 No. 1 (2010) Why data exclusivity is the new patent protection Peter J Pitts   Abstract Download PDF Commentary Vol.16 No. 1 (2010) Follow-on biologic drug competition – No need for new marketing exclusivities Michael S Wroblewski   Abstract Download PDF Articles Vol.16 No. 1 (2010) Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb Nigel Borshell The 25 per cent rule of thumb is often quoted in the context of licensing royalty rates and, in particular, when deriving an appropriate rate of income due to a licenso Abstract Download PDF Articles Vol.16 No. 1 (2010) Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms Mark J Ahn This paper provides an empirical analysis of leading global multinational pharmaceutical and biotechnology firms with respect to technology agglomeration patterns, prox Abstract Download PDF Articles Vol.16 No. 1 (2010) Intellectual property landscape and patenting opportunity in biofuels Ramasamy Mannan The oil embargo of the 1970s forced a realisation that our fossil fuel resources are finite and fast dwindling. Three decades later, this realisation is once again hitt Abstract Download PDF Articles Vol.16 No. 1 (2010) Challenges and opportunities in the licensing of renewable technologies Meredith Lloyd-Evans This paper briefly describes a new initiative dedicated to licensing of renewables, then moves on to some of the issues and challenges in the establishment and licensin Abstract Download PDF Articles Vol.16 No. 1 (2010) Ethiopia: Biotechnology for development Desta Berhe Sbhatu This article was written to provide compelling rationales for initiating biotechnology education, and a research and development programme in one technology institute i Abstract Download PDF Articles Vol.16 No. 1 (2010) Innovation and commercialisation in the stem cell industries in Australia: State strategies and other opportunities to build a competitive position in the global stem cell economy Olivia Harvey Recent research in the social studies of stem cell science has demonstrated that there is (a) a significant global economy emerging around stem cell science, and (b) th Abstract Download PDF Legal and Regulatory Updates Vol.16 No. 1 (2010) Using IP audits to optimize IP assets James G Cullem Obtaining, maintaining and leveraging intellectual property (IP) rights on important or critical technologies requires a significant investment of both money and time. Abstract Download PDF Book Reviews Vol.16 No. 1 (2010) Book Review: Health-care investing: Profiting from the new world of pharma, biotech and health-care services Frank LaSaracina Health-care investing: Profiting from the new world of pharma, biotech and health-care servicesLes FuntleyderMcGraw-Hill Professional, New York, 2009, hardback, 304pp.,< Abstract Download PDF Book Reviews Vol.16 No. 1 (2010) Book Review: Aging, Biotechnology, and the Future Harley King Aging, Biotechnology, and the FutureCatherine Y. Read, Robert C. Green and Michael A. SmyerThe Johns Hopkins University Press, Baltimore, 2008, hardback, 250pp.,ISBN: Abstract Download PDF
